BackgroundOpioid overdose remains a leading cause of preventable death in the United States. Existing approaches to identify individuals at elevated risk rely on imprecise rule-based criteria that misclassify patients’ risk of this serious health outcome. Machine learning (ML) algorithms can help improve prediction performance and can be combined with electronic health record (EHR) interventions to reduce overdose risk. ObjectiveThe Machine Learning Prediction and Reducing Overdoses With EHR Nudges (mPROVEN) clinical trial integrates a validated ML overdose risk model with behavioral economics–informed EHR nudges to test whether the combination improves evidence-based prescribing behaviors associated with lower overdose risk and, ultimately, reduces overdose among elevated-risk patients. MethodsmPROVEN is a pragmatic cluster randomized controlled trial conducted in primary care practices within a large multistate integrated health system. Eligible patients are adults (≥18 years) identified by the ML algorithm as having elevated overdose risk and seen at a primary care visit during the study period. Primary care practices serve as the unit of randomization and will be randomized into three arms: (1) usual care; (2) elevated risk flag only, where clinicians see a noninterruptive EHR flag indicating elevated overdose risk; and (3) elevated risk flag + nudges, in which active choice and accountable justification alerts are embedded within the EHR in addition to the elevated risk flag. The trial will enroll a target cohort of 800 patients for the primary analysis. The intervention period is 4 months (or until the study ends, whichever occurs later). The primary outcome is a 3‑point composite measure of safer opioid prescribing at 4 months, awarding 1 point each for active naloxone prescription, average opioid dosage of 50 morphine milligram equivalents per day or less, and absence of opioid-benzodiazepine overlap. Secondary outcomes include the composite outcome at 6 months, individual score components, and all-cause and overdose-specific emergency department or inpatient visits. Outcomes will be compared across study arms using an intention‑to‑treat approach with linear mixed‑effects models accounting for clinic-level clustering. ResultsFunded by the National Institutes of Health, in June 2022, enrollment began on March 10, 2025. Enrollment for the primary analysis cohort (n=798) was completed in May 2025 with additional participants enrolled for secondary analyses through December 2025 (n=1662). Primary cohort analyses began in January 2026, and results are expected by mid-2027. ConclusionsThe mPROVEN study is among the first pragmatic randomized controlled trials to integrate ML‑based opioid overdose risk prediction with behavioral nudges within a large health system EHR. By combining advances in data science and behavioral economics, the study aims to reduce opioid overdose risk in primary care using a scalable and low-touch intervention to address a high-priority public health issue. Trial RegistrationClinicalTrials.gov NCT06806163; https://clinicaltrials.gov/study/NCT06806163 International Registered Report Identifier (IRRID)DERR1-10.2196/94007

BACKGROUND:Hospitalization for alcohol use disorder (AUD) offers an opportunity to initiate evidence-based medications for alcohol use disorder (MAUDs). OBJECTIVE:To describe patterns and factors associated with hospital initiation of MAUD. DESIGN:Retrospective cohort study. SETTING:Veterans Health Administration (VHA). PARTICIPANTS:Veterans hospitalized with a primary diagnosis of AUD in 2022 or 2023. MEASUREMENTS:Patients had MAUD initiated as an inpatient or within 7 days of discharge. Logistic regression models estimated the predicted probabilities of MAUD initiation based on hospital fixed effects and demographic and clinical characteristics. RESULTS:Among 29 041 hospitalizations for AUD of veterans without MAUD at baseline in 142 hospitals (median age, 55 years; 94% male), in 8932 hospitalizations (30.8%), MAUD was initiated as an inpatient or within 7 days; MAUDs were naltrexone (57.9%), acamprosate (16.5%), and injectable naltrexone (13.9%). Of MAUD initiations, 6221 (69.6%) were during an inpatient stay and the rest were within 7 days. Of the 6221 inpatient initiations, 97.7% had a prescription for MAUD within 30 days after discharge. In adjusted analyses, MAUD initiation was more likely for hospitalizations with a specialty addiction consultation and those receiving psychiatry versus medicine service. Initiation of MAUD was less likely for persons aged 65 years or older, men, American Indian or Alaska Native versus White veterans, frail veterans, veterans diagnosed with opioid use disorder, and those in the intensive care unit. The median hospital-level rate of MAUD initiation was 29.9% (IQR, 22.6% to 36.3%). LIMITATION:Generalizability to other health care systems. CONCLUSION:Within the VHA, 30% of hospitalizations for AUD resulted in MAUD initiation as an inpatient or within 7 days of discharge, with substantial variation across hospitals and patient demographic and clinical factors. These data indicate a need to identify and disseminate successful hospital-based strategies to increase prescribing of MAUD. PRIMARY FUNDING SOURCE:U.S. Department of Veterans Affairs and National Institute on Aging.

Importance:Veterans with mental health conditions (MHC) face unique challenges obtaining high-quality, coordinated health care. With a growing number of veterans receiving VA-purchased community care (CC) provided outside the Veterans Health Administration (VA), evidence is needed on how veterans in this high-prevalence, marginalized subgroup experience CC. Objective:To compare experiences with CC over time for US veterans with and without MHC. Design, Setting, and Participants:This retrospective, cross-sectional survey study analyzed responses to the Survey of Healthcare Experiences of Patients-Community Care Survey (SHEP-CCS) from 2016 to 2021. Ratings of CC were examined across 9 domains and compared for veterans with and without MHC, adjusting for differences in baseline characteristics using regression models. Data were analyzed from March 2023 to September 2024. Exposure:Diagnosis of MHC, defined as bipolar disorder, major depression, posttraumatic stress disorder, schizophrenia, or psychosis. Main Outcomes and Measures:Veterans' ratings of CC across 9 domains, overall satisfaction, overall clinician rating, clinician communication, eligibility determination, first appointment access, recent appointment access, nonappointment access, care coordination, and billing, were assessed on a scale of 1 to 100. Unadjusted annual ratings of care experiences were analyzed by survey domain. A series of 4 respondent-level linear regression models were examined for each domain and survey responses were pooled to test for differences in experiences between veterans with vs without MHC. Results:This study included 231 869 veterans, including 62 911 veterans with MHC (27.1%) and 168 958 without MHC (72.9%). Veterans with MHC had a mean (SD) age of 55.8 (14.7) years, 8327 were female (18.5%), and 24 792 had 3 or more comorbidities (29.9%). Veterans without MHC had a mean (SD) age of 62.5 (15.2) years, 11 277 were female (11.0%), and 49 689 had 3 or more comorbidities (24.0%). In fully adjusted models, veterans with vs without MHC had lower adjusted overall satisfaction with CC by -1.8 (95% CI, -2.3 to -1.3) points (P < .001). Ratings in all domains were lower for veterans with vs without MHC (-0.09 to -0.05 SDs of domain scores) (P < .001 for all comparisons). Although ratings improved from 2016 to 2021, significant differences persisted over time for veterans with vs without MHC for all domains. Conclusions and Relevance:In this survey study of veterans receiving CC from 2016 to 2021, those diagnosed with MHC reported lower ratings of CC across all measured domains, and these differences persisted over time. These findings highlight where focused care coordination and quality improvement efforts could improve CC experiences for this vulnerable subpopulation of veterans.

Background:Despite the morbidity and mortality associated with COVID-19 infection, vaccine hesitancy remains a barrier to uptake. This article assessed whether unique clusters can be identified based on COVID-19-related thoughts and feelings and whether cluster membership is associated with COVID-19 vaccination. We also explored how individuals' thoughts, beliefs, and trust shape motivations and hesitancies for vaccine use. Methods:This mixed-methods quality improvement project was conducted from July 2021 through May 2022 in Primary Care at the Veterans Affairs Pittsburgh Healthcare System. The primary outcome was self-reported COVID-19 vaccination. K-means analysis were used to identify clusters based on questionnaire responses, and multivariable logistic regression were used to assess the association between cluster membership and vaccination. We conducted qualitative interviews with patients in the 2 clusters with the lowest vaccination rates to explore vaccination motivations and hesitancies. Results:Among 1208 respondents, 1034 (85.6%) were vaccinated. Four unique clusters were identified with vaccination rates of 29.9%, 93.3%, 93.5%, and 98.9%. Cluster membership was independently associated with vaccination, with adjusted odds ratios in the 3 most frequently vaccinated clusters of 12.1 (95% CI, 6.1-23.8), 13.0 (95% CI, 6.9-24.5), and 48.6 (95% CI, 15.5-152.0). Thematic analyses of 47 qualitative interviews found that protecting oneself and protecting others were the most common motivators for vaccination. The most common concerns were the rapid development of the vaccines and adverse effects, both more frequently endorsed in the cluster with the lowest vaccination rate. Conclusions:Unique patient clusters based on infection- and vaccine-related thoughts and feelings are independently associated with COVID-19 vaccination. Identifiable themes regarding vaccine uptake and hesitancy vary among these clusters. These themes can be used to tailor strategies to diminish vaccine hesitancy and augment vaccination uptake among veterans.

Background: Atrial fibrillation (AF) is associated with stroke and mortality. Research has demonstrated racial and ethnic disparities in AF outcomes, yet our understanding of the determinants of these disparities is limited. Objectives: The authors compared stroke and mortality by race and ethnicity for AF patients in the Veterans Health Administration. Methods: We identified Veterans Health Administration patients with incident AF from January 1, 2014, to December 31, 2021, with follow-up through May 31, 2022. Our independent variables were race (American Indian/Alaska Native (AI/AN), Asian, Black, and White) and ethnicity (Hispanic). Our primary outcomes were stroke and mortality incidence. Cox proportional hazard models assessed the association between race, ethnicity, and our outcomes, adjusting for sociodemographic, clinical, and facility factors. Results: Our cohort included 157,332 patients with AF; mean age 72.9 ± 10.5 years, 97.8% male and 2.2% female. Overall, 22,628 (14.7%) patients developed stroke (46.3 per 1,000 person-years), and 52,288 (33.2%) patients died (96.1 per 1,000 person-years). The adjusted HR (aHR) for stroke was higher for Black (aHR: 1.14; 95% CI: 1.09-1.20) than White patients, with no differences observed between AI/AN, Asian, or Hispanic and White patients. Mortality was lower for Asian (aHR: 0.85; 95% CI: 0.78-0.93), Black (aHR: 0.92; 95% CI: 0.89-0.95), and Hispanic (aHR: 0.82; 95% CI: 0.77-0.87) than White patients, with no difference observed for AI/AN patients. Conclusions: In a nationwide cohort of AF patients, we found significantly higher stroke rates for Black than White patients. Conversely, we observed significantly lower mortality rates for Asian, Black, and Hispanic patients than for White patients. Interventions to address factors associated with these disparities are essential.

BACKGROUND:The Department of Veterans Affairs (VA) now offers eligible Veterans an urgent care benefit covering visits and 14-day prescriptions outside of VA. Prescriptions written and dispensed outside VA lack the clinical decision support of VA-issued prescriptions, raising concerns about safety and polypharmacy. To date, there has been limited analyses of prescribing patterns through the urgent care benefit. METHODS:We used a repeated cross-sectional design to examine Veterans who filled non-VA urgent care prescriptions from 07/30/2019 to 03/20/2023. Data were sourced from the Community Care Reimbursement System (CCRS), which tracks all VA-paid medications dispensed by non-VA pharmacies. We identified potentially noncompliant prescriptions as those not meeting VA urgent care benefit restrictions. We also identified prescriptions continued in VA as a "new VA medication" after 30-days from the urgent care fill. RESULTS:Overall, 83,862 Veterans received 271,476 non-VA urgent care prescriptions. Veterans' average age was 55.9, with 79.3 % male, 73.0 % White, 86.7 % non-Hispanic, and 41.4 % rural dwelling. Urgent care use increased from 341 prescription fills in March 2020 to 9738 in January 2023. Frequently filled prescriptions included antimicrobials (n = 114,492, 42.2 %) and hormones/synthetics/modifiers, like steroids (n = 44,457, 16.4 %). Potentially noncompliant prescriptions accounted for 9.3 %, with 6.7 % not on the urgent/emergent formulary and 2.6 % supplied for over 14 days. Over 70,704 (26.0 %) prescriptions were continued in VA post-urgent care visit, of which 15 % had no prior VA fill (i.e., new VA medication). Veterans with new continued VA prescriptions were more likely to be male (79.4 % vs. 73.9 %) and from urban areas (59.3 % vs. 57.5 %) (All P < .001). CONCLUSIONS:Veterans increasingly received non-VA prescriptions through urgent care centers in the community from 2019 to 2023, including drug classes of interest to VA due to potential risks of inappropriate prescribing (e.g., steroids) or drug interactions (e.g., antibiotics). The CCRS database can be integrated with other VA databases as a quality improvement tool to improve care coordination and drug safety. IMPLICATIONS:This evaluation highlights the need for improved clinical decision support for non-VA prescriptions and demonstrates the potential of integrated data systems to monitor and enhance medication safety and coordination within VA. LEVEL OF EVIDENCE:Cross-sectional analysis of national VA data.

OBJECTIVE:To examine whether eligibility for Veterans Health Administration (VA) community care, which expanded Veterans' access to VA-funded care outside VA, increased the likelihood of Veterans concurrently filling prescriptions for opioids and central nervous system (CNS)-active medications. STUDY SETTING AND DESIGN:We used a regression discontinuity design to analyze Veterans across a distance threshold for community care eligibility in the Veterans Choice Program, under which Veterans residing > 40 miles from the closest VA medical facility staffed by ≥ 1 full-time primary care physician qualified for community care. We used local linear regression to test whether exceeding this 40-mile threshold was associated with discontinuities in the probability of receiving overlapping supplies of opioids and another CNS medication (benzodiazepine, muscle relaxant, antiepileptic, or sleep aid) for ≥ 30 days per year. DATA SOURCES AND ANALYTIC SAMPLE:We used VA pharmacy data for prescriptions filled at VA facilities, VA Program Integrity Tool files for prescriptions paid by VA and filled in community pharmacies, and Medicare and Medicaid data for prescriptions covered by those programs. Our analysis included annual cross-sectional samples of Veterans who filled ≥ 1 opioid prescription through VA, community care, Medicare, or Medicaid and lived 36-39 or 41-44 miles from the nearest VA facility during federal FYs 2016-2019 (n = 180,903 Veteran-year observations). PRINCIPAL FINDINGS:Among Veterans who filled an opioid prescription, 34.1% concurrently received another CNS medication for ≥ 30 days. Exceeding the threshold for community care eligibility was associated with a 1.14 percentage point (pp) increase (95% CI: 0.08, 2.20) in the probability of concurrently receiving an opioid and another CNS drug during 2016-2019. Discontinuities in overlap were larger among Veterans with a serious mental illness (2.7 pp.; 95% CI: 0.6, 4.9) during 2016-2019. During 2018-2019, discontinuities were larger in the overall sample (1.6 pp.; 0.0, 3.1) and among non-Hispanic Black Veterans (5.4 pp.; 95% CI: 0.5, 10.4). CONCLUSIONS:Overall, VA community care eligibility was associated with a small increase in medication overlap involving opioids and other CNS-active medications. Increases in overlap were larger in certain Veteran subgroups and later study years, underscoring a need for continued monitoring of higher-risk co-prescribing in VA community care.

Prior research documented racial and ethnic disparities in health care experiences within the Veterans Health Administration (VA). Little is known about such differences in VA-funded community care programs, through which a growing number of Veterans receive health care. Community care is available to Veterans when care is not available through the VA, nearby, or in a timely manner. To examine differences in Veterans’ experiences with VA-funded community care by race and ethnicity and assess changes in these experiences from 2016 to 2021. Observational analyses of Veterans’ ratings of community care experiences by self-reported race and ethnicity. We used linear and logistic regressions to estimate racial and ethnic differences in community care experiences, sequentially adjusting for demographic, health, insurance, and socioeconomic factors. Respondents to the 2016–2021 VA Survey of Healthcare Experiences of Patients-Community Care Survey. Care ratings in nine domains. The sample of 231,869 respondents included 24,306 Black Veterans (mean [SD] age 56.5 [12.9] years, 77.5

Importance Racial and ethnic disparities exist in anticoagulation therapy for atrial fibrillation (AF). Whether medical center racial and ethnic composition is associated with these disparities is unclear. Objective To determine whether medical center racial and ethnic composition is associated with overall anticoagulation and disparities in anticoagulation for AF. Design, Setting, and Participants Retrospective cohort study of Black, White, and Hispanic patients with incident AF from 2018 to 2021 at 140 Veterans Health Administration medical centers (VAMCs). Data were analyzed from March to November 2023. Exposure VAMC racial and ethnic composition, defined as the proportion of patients from minoritized racial and ethnic groups treated at a VAMC, categorized into quartiles. VAMCs in quartile 1 (Q1) had the lowest percentage of patients from minoritized groups (ie, the reference group). Main Outcomes and MeasuresThe odds of initiating any anticoagulant, direct-acting oral anticoagulant (DOAC), or warfarin therapy within 90 days of an index AF diagnosis, adjusting for sociodemographics, medical comorbidities, and facility factors. Results The cohort comprised 89 791 patients with a mean (SD) age of 73.0 (10.1) years; 87 647 (97.6%) were male, 9063 (10.1%) were Black, 3355 (3.7%) were Hispanic, and 77 373 (86.2%) were White. Overall, 64 770 individuals (72.1%) initiated any anticoagulant, 60 362 (67.2%) initiated DOAC therapy, and 4408 (4.9%) initiated warfarin. Compared with White patients, Black and Hispanic patients had lower rates of any anticoagulant and DOAC therapy initiation but higher rates of warfarin initiation across all quartiles of VAMC racial and ethnic composition. Any anticoagulant therapy initiation was lower in Q4 than Q1 (69.8% vs 74.9%; adjusted odds ratio [aOR], 0.80; 95% CI, 0.69-0.92; P < .001). DOAC and warfarin initiation were also lower in Q4 than in Q1 (DOAC, 69.4% vs 65.3%; aOR, 0.85; 95% CI, 0.74-0.97; P < .001; warfarin, 5.4% vs 4.5%; aOR, 0.82; 95% CI, 0.67-1.00; P < .001). In adjusted models, patients in Q4 were significantly less likely to initiate any anticoagulant therapy than those in Q1 (aOR, 0.88; 95% CI, 0.78-0.99). Patients in Q3 (aOR, 0.75; 95% CI, 0.60-0.93) and Q4 (aOR, 0.69; 95% CI, 0.55-0.87) were significantly less likely to initiate warfarin therapy than those in Q1. There was no significant difference in the adjusted odds of initiating DOAC therapy across racial and ethnic composition quartiles. Although significant Black-White and Hispanic-White differences in initiation of any anticoagulant, DOAC, and warfarin therapy were observed, interactions between patient race and ethnicity and VAMC racial composition were not significant. Conclusions and Relevance In a national cohort of VA patients with AF, initiation of any anticoagulant and warfarin, but not DOAC therapy, was lower in VAMCs serving more minoritized patients.

Oral anticoagulation reduces stroke risk for patients with atrial fibrillation (AF). Prior research demonstrates lower anticoagulant prescribing in Black than in White individuals but few studies have examined racial differences in facility-level anticoagulant prescribing for AF. To assess variation in anticoagulant initiation by race within Veterans Health Administration (VA) facilities. Retrospective cohort study. Black and White patients enrolled in the VA with incident AF from 2020 through 2021. The primary outcome was rate of any anticoagulant initiation (i.e., warfarin or direct oral anticoagulant [DOAC]) or any DOAC therapy within 90 days of an AF diagnosis, overall and for Black and White patients at each facility. We also estimated the adjusted Black-White risk difference. In 82 VA facilities serving 26,832 Black and White patients, overall unadjusted rates of any anticoagulant therapy ranged from 56.8 to 87.1

Over half of veterans enrolled in the Veterans Health Administration (VA) are also enrolled in Medicare, potentially increasing their opportunity to receive low-value health services within and outside VA. To characterize the use and cost of low-value services delivered to dually enrolled veterans from VA and Medicare. Retrospective cross-sectional. Veterans enrolled in VA and fee-for-service Medicare (FY 2017–2018). We used VA and Medicare administrative data to identify 29 low-value services across 6 established domains: cancer screening, diagnostic/preventive testing, preoperative testing, imaging, cardiovascular testing, and surgery. We determined the count of low-value services per 100 veterans delivered in VA and Medicare in FY 2018 overall, by domain, and by individual service. We applied standardized estimates to determine each service’s cost. Among 1.6 million dually enrolled veterans, the mean age was 73, 97

BACKGROUND:Veterans dually enrolled in the Veterans Health Administration (VA) and Medicare commonly experience downstream services as part of a care cascade after an initial low-value service. Our objective was to characterize the frequency and cost of low-value cervical cancer screening and subsequent care cascades among Veterans dually enrolled in VA and Medicare. METHODS:This retrospective cohort study used VA and Medicare administrative data from fiscal years 2015 to 2019. The study cohort was comprised of female Veterans aged >65 years and at low risk of cervical cancer who were dually enrolled in VA and Medicare. Within this cohort, we compared differences in the rates and costs of cascade services related to low-value cervical cancer screening for Veterans who received and did not receive screening in FY2018, adjusting for baseline patient- and facility-level covariates using inverse probability of treatment weighting. RESULTS:Among 20,972 cohort-eligible Veterans, 494 (2.4%) underwent low-value cervical cancer screening with 301 (60.9%) initial screens occurring in VA and 193 (39%) occurring in Medicare. Veterans who were screened experienced an additional 26.7 (95% CI, 16.4-37.0) cascade services per 100 Veterans compared to those who were not screened, contributing to $2919.4 (95% CI, -265 to 6104.7) per 100 Veterans in excess costs. Care cascades consisted predominantly of subsequent cervical cancer screening procedures and related outpatient visits with low rates of invasive procedures and occurred in both VA and Medicare. CONCLUSIONS:Veterans dually enrolled in VA and Medicare commonly receive related downstream tests and visits as part of care cascades following low-value cervical cancer screening. Our findings demonstrate that to fully capture the extent to which individuals are subject to low-value care, it is important to examine downstream care stemming from initial low-value services across all systems from which individuals receive care.

Purpose:The 2024 ASHP Pharmacy Forecast identifies and contextualizes emerging issues and trends that will influence healthcare, health systems, and the pharmacy profession and provides recommendations to inform long-term strategic planning that should prompt action by pharmacists and health-system leaders.Methods:Drawing on the “wisdom of crowds” concept, a survey was constructed with 6 general themes, each with 6 to 9 focused statements and a seventh theme on preparedness (58 survey items in total). The size of and representation within the survey panel were intended to capture opinions from a wide range of pharmacy leaders. The survey instructed panelists to consider the likelihood of the events/scenarios described in the statements occurring in the next 5 years as being likely, somewhat likely, somewhat unlikely, or very unlikely. Then, survey panelists assessed the preparedness (from very unprepared to very prepared) for 12 of the statements.Results:The 6 survey themes identified were Urgent Public Health Priorities, Responding to the Mental Health Crisis, Achieving Care Equity, New Disease Paradigms and Treatment Innovations, Workforce: Focus on Culture for the Future, and Artificial Intelligence: Can Ethics and Regulators Catch Up? The survey was completed by 250 respondents, yielding an 88% response rate. Analysis of survey results was provided by chapter authors along with strategic recommendations to guide actions for each theme.Conclusion:The focus of the Pharmacy Forecast is on large-scale, long-term trends that will influence healthcare and the pharmacy profession over months and years and not on day-to-day situational dynamics. The report provides insight to stimulate thinking and discussion and provides a starting point to proactively position leaders, their teams, and departments for potential future events and trends.

Objective Evaluate self-reported electronic screening (eScreening) in a VA Transition Care Management Program (TCM) to improve the accuracy and completeness of administrative ethnicity and race data.Materials and Methods We compared missing, declined, and complete (neither missing nor declined) rates between (1) TCM-eScreening (ethnicity and race entered into electronic tablet directly by patient using eScreening), (2) TCM-EHR (Veteran-completed paper form plus interview, data entered by staff), and (3) Standard-EHR (multiple processes, data entered by staff). The TCM-eScreening (n = 7113) and TCM-EHR groups (n = 7113) included post-9/11 Veterans. Standard-EHR Veterans included all non-TCM Gulf War and post-9/11 Veterans at VA San Diego (n = 92 921).Results Ethnicity: TCM-eScreening had lower rates of missingness than TCM-EHR and Standard-EHR (3.0% vs 5.3% and 8.6%, respectively, P < .05), but higher rates of "decline to answer" (7% vs 0.5% and 1.2%, P < .05). TCM-EHR had higher data completeness than TCM-eScreening and Standard-EHR (94.2% vs 90% and 90.2%, respectively, P < .05). Race: No differences between TCM-eScreening and TCM-EHR for missingness (3.5% vs 3.4%, P > .05) or data completeness (89.9% vs 91%, P > .05). Both had better data completeness than Standard-EHR (P < .05), which despite the lowest rate of "decline to answer" (3%) had the highest missingness (10.3%) and lowest overall completeness (86.6%). There was strong agreement between TCM-eScreening and TCM-EHR for ethnicity (Kappa = .92) and for Asian, Black, and White Veteran race (Kappas = .87 to .97), but lower agreement for American Indian/Alaska Native (Kappa = .59) and Native Hawaiian/Other Pacific Islander (Kappa = .50) Veterans.Conculsions eScreening is a promising method for improving ethnicity and race data accuracy and completeness in VA.

Introduction: Anticoagulation reduces stroke risk in atrial fibrillation (AF). Patient-level studies show significant Black-White disparities in any anticoagulant and direct oral anticoagulant (DOAC) prescribing. Little is known about whether such disparities exist at the hospital level, thus we examined the association of hospital racial composition and anticoagulant initiation. Hypothesis: Hospitals with higher rates of Black patients would have lower anticoagulation. Methods: We conducted a retrospective cohort study of patients with incident AF treated at a VA medical center (VAMC) from 2018-2021. Our independent variable was hospital racial composition, defined by the proportion of Black patients cared for at a VAMC, with Quartile 1 (Q1) being the lowest, and Quartile (Q4) being the highest. We used a multivariable logistic regression model, adjusting for clinical factors (e.g., stroke and bleeding risk), year of diagnosis, and region, to estimate the odds of any anticoagulant and/or DOAC initiation by hospital racial composition. Results: We identified 86,436 patients with incident AF at 140 VAMCs, 10.5% Black, 89.5% White, mean age 73 years. Patients in Q4 were younger with similar stroke and bleeding risk to those in Q1. Overall, any anticoagulant use was 73.4% in Q1 and 71.4% in Q4 and lower for Black vs. White patients in both quartiles (Q1: 68.9% vs. 73.5%; Q4: 69.1 vs. 72.0%). The odds of initiating any anticoagulant overall were lower in Q1 hospitals compared to Q4: adjusted odds ratio (aOR): 0.85; 95% CI 0.73-0.99; p=0.04. DOAC use was similar in Q1 and Q4 (67.6% vs. 67.2%) though lower for Black vs. White patients in both quartiles (Q1: 57.4% vs. 67.7%; Q4: 63.3 vs. 68.5%). There was no significant difference overall in the odds of initiating DOAC in Q1 hospitals compared to Q4, aOR: 0.96; 95% CI 0.83-1.12; p=0.61. Conclusions: In a national study of patients with AF in the VA, we observed a significant difference in any anticoagulant but not DOAC initiation by hospital racial composition. Racial differences in anticoagulant use existed across quartiles, as in prior work. These data suggest that racial disparities in anticoagulant use in the VA, a safety net health system, may require local rather than national-level solutions alone to eliminate them.

Background The Procalcitonin Antibiotic Consensus Trial (ProACT) found provision of a procalcitonin antibiotic prescribing guideline to hospital-based clinicians did not reduce antibiotic use. Possible reasons include clinician reluctance to follow the guideline, with an observed 64.8% adherence rate. In this study we sought to determine the threshold adherence rate for reduction in antibiotic use, and to explore opportunities to increase adherence. Methods This study is a retrospective analysis of ProACT data. ProACT randomized 1656 patients presenting to 14 U.S. hospitals with suspected lower respiratory tract infection to usual care or provision of procalcitonin assay results and an antibiotic prescribing guideline to the treating clinicians. We simulated varying adherence to guideline recommendations for low procalcitonin levels and determined which threshold adherence rate could have resulted in rejection of the null hypothesis of no difference between groups at alpha = 0.05. We also performed sensitivity analyses within specific clinical settings and grouped patients initially prescribed antibiotics despite low procalcitonin into low, medium, and high risk of illness severity or bacterial infection. Results Our primary outcome was number of antibiotic-days by day 30 using an intention-to-treat approach and a null hypothesis of no difference in antibiotic use. We determined that an 84% adherence rate in the hospital setting (emergency department and inpatient) for low procalcitonin could have allowed rejection of the null hypothesis (3.7 vs 4.3 antibiotic-days, p = 0.048). The threshold adherence rate was 76% for continued guideline adherence after discharge. Even 100% adherence in the emergency department alone failed to reduce antibiotic-days. Of the 218 patients prescribed antibiotics in the emergency department despite low procalcitonin, 153 (70.2%) were categorized as low or medium risk. Conclusions High adherence in the hospital setting to a procalcitonin antibiotic prescribing guideline is necessary to reduce antibiotic use in suspected lower respiratory tract infection. Continued guideline adherence after discharge and withholding of antibiotics in low and medium risk patients with low procalcitonin may offer impactful potential opportunities for antibiotic reduction. Trial registration Procalcitonin Antibiotic Consensus Trial (ProACT), ClinicalTrials.gov Identifier: NCT02130986. First posted May 6, 2014.

Low-value care cascades, defined as the receipt of downstream health services potentially related to a low-value service, can result in harm to patients and wasteful healthcare spending, yet have not been characterized within the Veterans Health Administration (VHA). To examine if the receipt of low-value preoperative testing is associated with greater utilization and costs of potentially related downstream health services in Veterans undergoing low or intermediate-risk surgery. Retrospective cohort study using VHA administrative data from fiscal years 2017–2018 comparing Veterans who underwent low-value preoperative electrocardiogram (EKG) or chest radiograph (CXR) with those who did not. National cohort of Veterans at low risk of cardiopulmonary disease undergoing low- or intermediate-risk surgery. Difference in rate of receipt and attributed cost of potential cascade services in Veterans who underwent low-value preoperative testing compared to those who did not Among 635,824 Veterans undergoing low-risk procedures, 7.8% underwent preoperative EKG. Veterans who underwent a preoperative EKG experienced an additional 52.4 (95% CI 47.7–57.2) cascade services per 100 Veterans, resulting in $138.28 (95% CI 126.19–150.37) per Veteran in excess costs. Among 739,005 Veterans undergoing low- or intermediate-risk surgery, 3.9% underwent preoperative CXR. These Veterans experienced an additional 61.9 (95% CI 57.8–66.1) cascade services per 100 Veterans, resulting in $152.08 (95% CI $146.66–157.51) per Veteran in excess costs. For both cohorts, care cascades consisted largely of repeat tests, follow-up imaging, and follow-up visits, with low rates invasive services. Among a national cohort of Veterans undergoing low- or intermediate-risk surgeries, low-value care cascades following two routine low-value preoperative tests are common, resulting in greater unnecessary care and costs beyond the initial low-value service. These findings may guide de-implementation policies within VHA and other integrated healthcare systems that target those services whose downstream effects are most prevalent and costly.